drugset / Trial / NCT02984397
Chronic Widespread Pain and White Blood Cell Activation
Phase 3
Completed
44 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
The Louise And Alan Edwards Foundation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Our goal is to conduct a proof-of-concept trial to test the efficacy of KF treatment in adolescents with severe CWP not responding to the standard of care (SOC) treatment program in a multidisciplinary tertiary care chronic pain clinic. The changes associated to the interventions (KF or placebo) will be quantified using the Patients' Global Impression of Change (PGIC) scale after 16 weeks of treatment. Secondary, we aim to evaluate the effects of KF on the pain sensitivity, physical and emotional functioning, and we will also explore the potential biological underlying mechanisms.
Timeline
- Start
- 2016-12
- Primary completion
- 2020-01
- Completion
- 2020-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketotifen | Small molecule | 3 mg | — |